https://tavanta.tasnadi.group/press-release/druggability-technologies-holdings-ltd-drgt-announces-appointment-of-a-new-chief-executive-officer-and-new-president-of-drgt-research/ 2020-08-10T16:40:19+00:00 https://tavanta.tasnadi.group/press-release/drgt-announces-the-u-s-fda-ind-application-approval-and-first-dosing-of-a-clinical-trial-to-evaluate-the-bioavailability-and-food-effect-of-immediate-release-formulation-of-tadalafil-drgt-99/ 2020-08-10T16:42:01+00:00 https://tavanta.tasnadi.group/press-release/drgt-announces-hungarian-regulatory-authority-approval-and-subsequent-initiation-of-a-phase-2-trial-of-drgt-119-in-patients-with-chronic-anal-fissure/ 2020-08-10T16:42:13+00:00 https://tavanta.tasnadi.group/press-release/drgt-usa-announces-appointment-of-dr-elizabeth-manning-duus-as-executive-director-of-clinical-development/ 2020-08-10T16:43:23+00:00 https://tavanta.tasnadi.group/press-release/druggability-technologies-usa-announces-appointment-of-john-e-friend-ii-m-d-as-chief-medical-officer/ 2020-08-10T16:44:07+00:00 https://tavanta.tasnadi.group/press-release/best-in-class-erectile-dysfunction-drug-drgt-announces-dose-escalation-study-results-of-its-super-tadalafil-drgt-99/ 2020-08-10T16:44:28+00:00 https://tavanta.tasnadi.group/press-release/drgt-announces-results-of-phase-i-study-expanding-clinical-utility-of-the-drug-sirolimus-utilizing-the-companys-novel-super-api-technology-platform/ 2020-08-10T16:44:29+00:00 https://tavanta.tasnadi.group/press-release/drgts-novel-celecoxib-composition-opportunity-for-low-dose-immediate-onset-of-pain-relief-with-the-only-nsaid-cox-2-inhibitor-on-the-market/ 2020-08-10T16:45:14+00:00 https://tavanta.tasnadi.group/press-release/dr-philip-kantoff-leading-expert-in-clinical-oncology-and-prostate-cancer-joins-drgt-as-senior-clinical-advisor/ 2020-08-10T16:45:30+00:00 https://tavanta.tasnadi.group/press-release/drgts-novel-abiraterone-acetate-composition-provides-opportunity-for-dose-reduction-and-increased-efficacy-in-prostate-cancer/ 2020-08-10T16:46:02+00:00 https://tavanta.tasnadi.group/press-release/druggability-technologies-enters-into-a-strategic-collaboration-with-bayer-healthcare/ 2020-08-10T16:46:20+00:00 https://tavanta.tasnadi.group/press-release/quotient-clinical-begins-prostate-cancer-project-for-druggability-technologies/ 2020-08-10T16:46:24+00:00 https://tavanta.tasnadi.group/press-release/drgt-completes-a-pivotal-phase-i-trial-results-confirm-6x-faster-attainment-of-maximum-plasma-levels-for-pain-management-compared-to-currently-available-cox-2-inhibitor/ 2020-08-10T16:47:42+00:00 https://tavanta.tasnadi.group/press-release/drgt-announces-first-subject-dosed-in-a-phase-i-clinical-trial-of-drgt-45-a-novel-formulation-of-abiraterone-acetate-for-prostate-cancer/ 2020-08-24T04:57:02+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-new-specialty-pharmaceutical-company-has-diverse-pipeline-of-novel-drugs-and-risk-balanced-approach-to-product-development/ 2020-08-31T20:41:11+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-announces-first-patient-dosed-in-phase-3-clinical-trial-of-tavt-45-abiraterone-acetate-granules-for-oral-suspension-a-novel-formulation-of-abiraterone-acetate-for-the-treatmen/ 2021-05-25T12:00:30+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-announces-new-appointments-to-strengthen-its-executive-and-senior-leadership-teams/ 2021-07-13T10:16:19+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-announces-completion-of-enrollment-in-pivotal-phase-3-trial-of-tavt-45-for-the-treatment-of-metastatic-prostate-cancer/ 2022-08-02T05:42:10+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-to-present-preclinical-data-for-tavt-135-at-the-north-american-cystic-fibrosis-conference/ 2022-11-02T08:01:05+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-announces-positive-top-line-results-from-pivotal-phase-3-trial-of-tavt-45-for-the-treatment-of-metastatic-prostate-cancer/ 2023-03-21T15:07:25+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-announces-new-preclinical-data-for-its-cystic-fibrosis-candidate-tavt-135-at-two-prominent-scientific-conferences/ 2023-05-24T15:06:52+00:00 https://tavanta.tasnadi.group/press-release/tavanta-therapeutics-to-showcase-specialty-pipeline-during-the-2023-american-society-of-clinical-oncology-asco-and-american-society-of-colon-and-rectal-surgeons-ascrs-annual-congresses/ 2023-05-31T12:22:56+00:00